Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cempra planning follow-on

Cempra Inc. (NASDAQ:CEMP) proposed a follow-on late Thursday underwritten by Barclays; Stifel; and Cowen. Cempra

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE